Next Article in Journal
Lower Interhemispheric Coherence in Adults with Surgically Treated Severe Generalized Epilepsy than in Patients Without Epilepsy: A Scalp EEG Study
Previous Article in Journal
Kernel-Transformed Functional Connectivity Entropy Reveals Network Dedifferentiation in Bipolar Disorder
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 16
Issue 2
10.3390/brainsci16020209
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece

by
Michel B. Janho
1,*,
Maria N. Papaliaga
2,
Athina A. Samara
3,
Stamatia Papoutsopoulou
4,
Matthaios Speletas
5,
Nikolaos Christodoulou
2 and
Eftihia Asprodini
1
1
Department of Clinical Pharmacology, Faculty of Medicine, University of Thessaly, 411 10 Larisa, Greece
2
Department of Psychiatry, University Hospital of Larissa, 411 10 Larisa, Greece
3
Faculty of Public and One Health, University of Thessaly, 431 00 Karditsa, Greece
4
Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 413 34 Larissa, Greece
5
Department of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, 382 21 Volos, Greece
*
Author to whom correspondence should be addressed.
Brain Sci. 2026, 16(2), 209; https://doi.org/10.3390/brainsci16020209
Submission received: 9 January 2026 / Revised: 26 January 2026 / Accepted: 6 February 2026 / Published: 10 February 2026
(This article belongs to the Section Neuropsychiatry)
Browse Figures
Versions Notes

Highlights

What are the main findings?
  • Elevated caffeine serum levels are correlated with impaired attention.
  • Violent behavior is seen more commonly as caffeine serum levels increase.
What are the implications of the main findings?
  • Caffeine may have a paradoxical effect on attention in patients with schizophrenia.
  • The introduction of routine caffeine monitoring may help manage patients prone to aggressive behavior.

Abstract

Introduction: Caffeine is the most consumed psychostimulant worldwide. Schizophrenia is an uncommon mental disorder affecting 0.34% of the global population. The aim of the current study was to investigate a possible association between caffeine consumption and symptom profile, dangerous behavior, and cognitive functions in patients with schizophrenia. Methods: This prospective cohort study included consecutive patients diagnosed with schizophrenia who were admitted to the psychiatry ward or visited the psychiatry outpatient clinics at a tertiary University Hospital in Greece for a period of 12 months. All patients underwent an extensive psychiatric and cognitive function assessment using the standardized Greek version of the Positive and Negative Symptom Scale (PANSS), the generalized anxiety disorder scale (GAD-7), and the Addenbrooke cognitive test (ACE-R). Results: In total, 53 patients were included in the present study. Mean age of the participants was 45 ± 11 years. The mean age at onset was 23 ± 7 years, while mean duration of illness from age of onset was 21.58 years. Caffeine serum levels exhibited a positive correlation with the poor attention component of the general psychopathology PANSS subscale, as well as with the attention and orientation component in the ACE-R. Moreover, another positive correlation was observed between the perilous behavior PANSS subscale and caffeine serum levels. Conversely as caffeine serum levels increased, fewer negative symptoms were reported, specifically, the poor rapport and passive/apathetic social withdrawal of the negative PANSS subscale. Conclusions: In summary, this study highlights the significant associations between caffeine serum levels, symptom severity, and cognition among patients with schizophrenia. While the findings provide valuable insights, they should be interpreted with caution due to the study’s several limitations. More larger scale cohort studies are needed in order to elucidate the impact of caffeine consumption in patients with schizophrenia.

Graphical Abstract

1. Introduction

Background/Rationale

Caffeine is the most consumed psychostimulant worldwide [1]. It is naturally found in coffee, tea, and cocoa, while it can also be found in chocolate, energy drinks, and caffeinated soft drinks [2,3]. Coffee and tea are the most consumed caffeine containing beverage amongst adults while chocolate, energy drinks and caffeinated soft drinks are consumed mainly by adolescents and children [4,5]. Recent worldwide statistics showed that global coffee consumption amounted to approximately 177 million 60 kg bags of coffee in 2023/2024, a 2.3% increase from the previous year [6].
Consuming caffeine results in 99% absorption after about 45 min [7,8,9]. Delayed absorption of caffeine, however, is observed after cola or chocolate consumption [10]. Caffeine can pass through all biological membranes owing to its hydrophobic properties [11] and, therefore, can pass freely through the blood–brain barrier [12]. Moreover, the pharmacokinetics of caffeine in blood and cerebrospinal fluid are similar [13]. Caffeine is metabolized in the liver mainly (95%) by CYP1A2 [14] into its main active metabolite paraxanthine [15] and to a lesser effect by CYP3A4, xanthine oxidase, and N-acetyltransferase 2 [16,17]. Other known metabolites are theobromine and theophylline, which are also biologically active. A plethora of factors can influence CYP1A2 activity and ultimately contribute to variations in caffeine metabolism. These include gender, race, single nucleotide polymorphisms, and exposure to inhibitors/inducers (e.g., smoking) [1,14,15,18]. The metabolites are excreted in urine [15] alongside less than 2% of unchanged caffeine [19].
Schizophrenia is an uncommon mental disorder affecting 0.34% of the global population, according to the latest 2023 IHME global burden of disease study [20]. Although often thought to affect men and women equally, schizophrenia occurs marginally more frequently in men than in women (male-to-female incidence rate ratio of 1.7 [95% CI 1.46–1.97]) [21]. The main clinical features of schizophrenia include positive symptoms or reality distortion symptoms (e.g., delusions, hallucinations, and thoughts of suspiciousness), negative symptoms (e.g., lack of volition, reduced speech output, and blunt affect), and the disorganization syndrome (e.g., disorganized behavior and the uncommon symptom of inappropriate affect) [22,23]. Cognitive impairment is now considered an additional clinical feature of schizophrenia [24]. This impairment varies greatly in degree, as reported by a plethora of studies, ranging from little [25] to none [26] to large deficits across memory, orientation, and general knowledge domains [27]. Moreover, distinct limitations are observed in executive function, memory, and sustained attention [28,29]. The pathogenesis of schizophrenia has been hypothesized as a dysfunction of the dopamine [30,31] or glutamate [32,33] systems in the brain. Recently, the purinergic hypothesis of schizophrenia has emerged, proposing that reduced adenosinergic activity may underlie and integrate previously suggested mechanisms of the disorder [34].
The stimulant effects of caffeine on the central nervous system can be explained by its competitive antagonism against endogenous adenosine on A1 and A2A adenosine receptors [35,36,37]. Stimulation of the central nervous system at low caffeine doses (100 mg) increases locomotor activity [1,38] as well as arousal [39] but can manifest anxiety at higher doses (500 mg) [40,41]. Furthermore, improvements in cognitive functions have been reported after caffeine consumption on a regular basis, namely reaction time [42,43] and verbal memory [42,44]. On the other hand, acute administration of caffeine has been reported to improve sustained attention [45,46].
Adenosine, on the other hand, functions as a neuromodulator in both the dopaminergic and glutamatergic systems [47]. Specifically, adenosine A1 and A2A receptors form heteromers with dopamine D1 and D2 receptors in the striatum [48,49], resulting in the inhibition of dopamine signaling [50] as well as decreasing dopamine D2 affinity for agonists [51]. Adenosine modulates glutamate transmission in a concentration-dependent manner in the corticostriatum; low adenosine concentration inhibits glutamate release via the adenosine A1 receptor, and high adenosine concentration leads to glutamate potentiation via activation of the adenosine A2A receptor, which in turn inhibits the A1 receptor and its aforementioned inhibitory effects on glutamate release [52,53]. The hypothesized hypofunctioning of the adenosinergic system in schizophrenia implies that the interaction of adenosine/dopamine heteromers as well as adenosine/glutamate heteromers via glutamate metabotropic receptors (mGluRs) [54,55] are hindered to a larger extent by the antagonistic effect of caffeine on adenosine receptors, thus enhancing this hypofunctioning and worsening schizophrenia symptoms. Consequently, many attempts have been made to reverse engineer medications based on this interaction to treat schizophrenia but without solid evidence [56].
Caffeine consumption by patients with schizophrenia can reach doses as high as 500 mg/day based on real-world data reports [57,58]. Conversely, daily doses up to 400 mg/day (around 2–4 cups of coffee or up to 6 cups of tea) are considered safe in non-pregnant adults according to the scientific opinion by the European Food Safety Authority (EFSA) [14]. Beyond this limit, caffeinism can occur which can manifest as nausea, vomiting, tachycardia, tachypnea, depressed consciousness, irritability, and headache. The implications, following profound caffeine consumption in this subpopulation, are well documented and they include cases of de novo psychosis [59,60] or deterioration of stable patients with schizophrenia [61,62]. Moreover, data regarding the effects of caffeine on cognition in patients with schizophrenia are sparse with mixed results [63,64].
Serum caffeine levels in patients with schizophrenia have not been extensively investigated in the current literature and, except for a few solitary case reports where lethal caffeine levels ranged from 80 mg/L to 100 mg/L [65,66,67,68], there are no standardized caffeine serum levels generally accepted as normal. A double-blind placebo-controlled study of patients with schizophrenia reported increased scores on psychopathology scales such as thought disorder, unusual thought content, and euphoria activation after acute administration of caffeine (10 mg/kg) [69]. A 2004 case control study reported higher serum caffeine levels in patients with schizophrenia versus healthy controls, but this difference was present only among smokers [70]. A few studies, on the other hand, have examined the relationship between caffeine serum levels and illness severity in patients with schizophrenia [69,71], while others examined reported caffeine intake with illness severity [72,73] with conflicting results and recommended more precise measures of caffeine intake [73].
Thus, given the knowledge gap in the literature accompanied by the mixed outcomes, the aim of the current study was formed to investigate any possible associations between caffeine consumption and symptom profile, dangerous behavior, and cognitive functions in patients with schizophrenia.

2. Methods

2.1. Study Design

This was a prospective cohort study including patients diagnosed with schizophrenia according to ICD-10 diagnostic criteria. Subjects with schizophrenia who are followed up on a regular basis at the outpatient clinic were enrolled.

2.2. Setting

This study recruited all consecutive patients who were admitted to the psychiatry ward or visited the psychiatry outpatient clinics at a tertiary University Hospital in Greece for a period of 12 months (June 2023–May 2024).

2.3. Participants

Eligibility criteria included adult patients aged 18 to 70 years old suffering from all subtypes of schizophrenia. The exclusion criteria were a personal history of alcohol/substance use disorder, severe physical illness, or pregnancy.

2.4. Data Sources/Measurements

Demographic data were recorded, including age, body mass index (BMI), sex, age at onset of disease, smoking status, and current antipsychotic medication. Prior to enrollment patients were examined by an experienced psychiatrist (M.P.) and afterwards underwent an extensive psychiatric and cognitive function assessment using the standardized Greek version of the Positive And Negative Symptom Scale (PANSS) [74] based on the original PANSS [75], the generalized anxiety disorder scale (GAD-7) [76], and the Addenbrooke cognitive test (ACE-R) [77,78].
The PANSS includes 33 items. It is divided into 3 subscales: the positive symptom subscale with seven items (P1–P7), the negative symptom subscale with seven items (N1–N7), and the subscale of general psychopathology with 16 items (G1–G16). The Greek standardized version further includes 3 items (anger intolerance to deferred gratification and emotional volatility; E1–E3) evaluating patients’ perilous behavior. Each item is graded on a 7-point system with higher scores corresponding to incremental levels of psychopathology (1 = absent to 7 = extreme). The final score results from the sum of the positive symptom subscale (7–49), the negative symptom subscale (7–49), and the subscale of general psychopathology (16–112), as well as the subscale for evaluating perilous behavior (3–21) [74].
The GAD-7 consists of 7 anxiety related questions corresponding to symptoms patients might be facing on a day-to-day basis. The questions are based on the diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders and graded according to their frequency. Each item is graded from 0 = not at all to 3 = nearly every day [76].
The Addenbrooke Cognitive Examination is a brief 15 min questionnaire exploring five cognitive domains. These include language, verbal fluency, attention, memory, and visuo-spatial ability. The scores on each individual domain are noted and summed up. Higher total score indicates better cognitive function up to a maximum of 100. Scores below 88 are indicative of a diagnosis of dementia [78,79].
The assessment of caffeine dietary intake included questions regarding the varieties of caffeinated products (coffee, tea, chocolate, cocoa, energy drinks), time of consumption throughout the day, quantities consumed per day, and the last time the patients consumed a caffeine-containing product. The dietary intake of caffeine-containing products was assessed by the examiner.
Blood was drawn from all participants for general hematologic and biochemical assays, as well as for measuring the caffeine blood levels and its metabolites, at the time of assessment. The mean time interval of caffeine consumption was 9:00 a.m. The mean time of blood drawing was 12:00 p.m. to control for caffeine consumption (the time of blood drawing varied from late morning to afternoon hours).
To quantify the concentration of caffeine and its metabolites, whole blood samples were centrifuged at 4000 rpm for 5 min, and blood serum aliquots of 1 mL were stored at −20° until they were batch processed. High pressure liquid chromatography with detection under ultraviolet light (HPLC-UV) was employed for the quantification of caffeine and its metabolites. This was a modified version of the method developed by Begas et al. [80]. The lower limit of quantification (LLOQ) for caffeine was 0.125 μg/mL. Participants exhibiting levels of caffeine below the LLOQ were considered non-caffeine consumers.

2.5. Variables

Duration of illness was calculated as the time from onset of schizophrenia to participation in the study. Antipsychotic medication was converted to chlorpromazine (CPZ) equivalents [81,82].

2.6. Study Size

A sample size of 60 was calculated in the power analysis whilst achieving a confidence level of 99.99% and a ±5% margin of error. This analysis was derived from the global incidence of schizophrenia which is approximately 1% [83,84] and from the population of Larissa which was around 164,095 inhabitants according to the latest survey in 2021 [85].

2.7. Statistics

The mean and standard deviation were used to describe continuous variables, whilst numbers and percentages were used to describe categorical variables. Nonparametric statistical tests were deployed. These included the Mann–Whitney U test and the Spearman’s correlation coefficient. All analyses were performed using SPSS version 26 (Chicago, IL, USA).

2.8. Ethical Considerations

Study design was in accordance with Declaration of Helsinki. No intervention or experimental treatment were used in the present study. The study protocol was approved by the Ethical Review Board of both the University General hospital of Larissa and the Faculty of Medicine of the University of Thessaly in January 2021.

3. Results

In total, 53 patients were included in the present study (Table 1). The mean age of the participants was 45 ± 11 years. The mean age at onset was 23 ± 7 years, while the mean duration of illness from the age of onset was 21.58 years. The majority of patients were males (75%), and 25 patients were current smokers. The mean BMI was calculated at 28.98 ± 6.34 kg/m2. Twenty-nine patients were hospitalized due to relapse of schizophrenia, presenting as an acute psychotic episode, and 25 were stabilized for at least 3 months and under regular monitoring on an outpatient basis. The mean CPZ equivalent was measured at 691.83 ± 425.37 mg. The distribution of caffeine serum levels is depicted in Supplementary Figure S1.

3.1. PANSS Arm

Table 2 displays the main results regarding the PANSS score. The mean PANSS total score was measured at 72 ± 21. Specifically, patients exhibited 15 ± 8 mean scores in the positive subscore, 21 ± 7 in the negative subscore, 7 ± 4 in the perilous behavior subscore, and 30 ± 9 in the general psychopathology subscore. The median serum caffeine levels were 0.543 ± 2.451 μg/mL.
Table 3 presents the statistical results regarding the caffeine consumption, the PANSS subscores, and their subsequent component items. A statistically significant difference in distribution was observed in both the poor rapport (p = 0.017) and passive/apathetic social withdrawal (p = 0.028) component items of the negative PANSS subscore. Moreover, the perilous behavior PANSS subscore (p = 0.002) and its components anger (p = 0.013), intolerance to deferred gratification (p = 0.026), and emotional volatility (p = 0.001) were also found to be statistically significant distributed between caffeine consumers and non-consumers. Finally, mannerism and posturing (p = 0.027), poor attention (p = 0.033), and active social avoidance showed a statistically significant difference across groups in the general psychopathology PANSS subscore (Figure 1).
In order to further investigate our results, nonparametric correlations using the Spearman’s rho coefficient were carried out (Table 4). A statistically significant positive correlation was found between caffeine levels and the excitement (r = 0.41, p = 0.012) and hostility (r = 0.276 p = 0.045) components of the positive PANSS subscore. In the same manner, the perilous behavior PANSS subscore (r = 0.435, p = 0.001) and its components anger (r = 0.335, p = 0.014), intolerance to deferred gratification (r = 0.357, p = 0.026), and emotional volatility (r = 0.464, p = 0.001) showed a positive correlation with caffeine levels. On the other hand, poor rapport (r = −0.349, p = 0.010) and passive/apathetic social withdrawal (r = −0.387, p = 0.004) exhibited a statistically significant negative correlation with caffeine levels. In the general psychopathology subscore, poor attention (r = 0.337, p = 0.013) exhibited a statistically significant positive correlation with caffeine levels, while active social avoidance (r = −0.347, p = 0.011) exhibited a statistically significant negative correlation.

3.2. ACE-R Arm

Fifty patients were included in the ACE-R arm (45 ± 11, 13 females and 37 males) (Table 1). The mean Addenbrooke total score was 75 ± 13 (Table 5). Specifically, patients exhibited 16 ± 2 mean scores in the attention and orientation subscore, 16 ± 6 in the memory subscore, 7 ± 3 in the fluency subscore, 22 ± 3 in the language subscore and 13 ± 2 in the visuo-spatial subscore. The median caffeine levels were 0.617 ± 2.503 μg/mL.
Similarly, a statistically significant difference in distribution of both the attention and orientation (p = 0.042) and memory (p = 0.005) was found. The ACE-R subscores were found to be statistically significant (Figure 2).
These differences were further explored by nonparametric correlations (Table 6) using the Spearman’s rho correlation coefficient, and a negative correlation was found for both attention and orientation (r = −0.335, p = 0.017) and language (r = −0.418, p = 0.003) ACE-R subscores and caffeine serum levels.

3.3. GAD-7 Arm

A finding worth mentioning is the fact that no correlation was found between the GAD-7 results and caffeine serum levels.

4. Discussion

The present observational prospective cohort study investigated a possible correlation between caffeine serum levels, cognitive functions, and symptom severity in patients with schizophrenia in the setting of a psychiatric department in a tertiary hospital. Caffeine serum levels exhibited a positive correlation with the poor attention component of the general psychopathology PANSS subscale, as well as with the attention and orientation component in the ACE-R. Moreover, another positive correlation was observed between the perilous behavior PANSS subscale and caffeine serum levels. Conversely, as caffeine serum levels increased, fewer negative symptoms were reported, specifically, the poor rapport and passive/apathetic social withdrawal of the negative PANSS subscale. In everyday clinical practice, our findings can be translated as patients with more negative symptoms, i.e., anhedonia and apathy, consume more caffeine, conceivably as a form of self-medication while increasing energy and motivation. However, we cannot suggest a clear causative association between aggressive behavior and caffeine consumption, as this correlation can be bidirectional.
Cognitive improvements in healthy individuals in relation to the consumption of caffeine have been reported extensively in the literature. Topyurek et al. [63] note in their invited commentary that cognitive enhancements in healthy individuals vary depending on whether caffeine is administered acutely or chronically. Acute administration of 4 mg/kg body weight [46] or 50/150/250 mg [45] caffeine versus placebo was associated with an increase in sustained attention. On the other hand, in a longitudinal study of 1876 individuals [43] and in a cross-sectional study of 140 individuals [86], chronic consumption of caffeine, measured on a self-report basis, was not associated with any changes in attention.
On the subject of schizophrenia, the only study exploring cognitive functions in patients with schizophrenia and their relationship with caffeine by Nunez et al. [64] associated better cognitive performance in male schizophrenia patients with caffeine consumption regarding domains such as semantic fluency, cognitive speed, working memory, and visual memory. Our results cannot be directly compared with the aforementioned study for several reasons: both genders are included, and different scores assessing cognitive functions were used. However, the fluency and memory ACE-R component exhibited no correlation with caffeine levels even after patients were grouped according to their caffeine consumption habits (caffeine and non-caffeine consumer). Conversely, caffeine serum levels exhibited a negative correlation with the ACE-R attention and orientation component as well as a positive correlation with the poor attention component of the PANSS general psychopathology subscale, i.e., attention worsens, as caffeine serum levels increase which is contrary to caffeine’s effects in healthy populations [45,46], albeit in the acute administration setting. A possible explanation for this phenomenon in this subpopulation could be hypothesized via caffeine’s antagonism on adenosine receptors in the hypofunctioning adenosergic network, which is responsible for arousal, according to the adenosine theory of schizophrenia [34]. Nevertheless, more research is needed to elucidate and to explore this association further.
Aggressive and violent behavior in schizophrenia are terms that exist along the same continuum. Aggression involves verbal threats of harm, while violence involves physical acts [87]. A study by Zislove et al. regarding caffeine consumption and aggression in psychiatric inpatients reported a statistically significant decrease during a one-year period in aggressive behavior, quantified by the need for seclusion of restraint, after the discontinuation of caffeinated beverages sales [88]. A similar study by Carmel [89] observed similar results in a different hospital albeit with no discontinuation of sales policy and highlighted that these differences could possibly arise from methodological differences as well as in discrepancies in reporting mechanisms of aggressive behaviors. It is worth noting that these studies covered all patients hospitalized in psychiatric wards irrelevant of their diagnosis. In the context of patients with schizophrenia, aggression can be quantified according to four standardized Greek PANSS components: hostility, anger, intolerance to deferred gratification, and emotional volatility. Given that the PANSS perilous behavior is used in clinical settings to predict the possible incidence of aggressive behavior in patients with schizophrenia, our results exhibited a positive correlation between all these four aforementioned components and caffeine serum levels, which translates to an increased probability of violent behavior as caffeine serum levels rise. We need to highlight the fact that there is a lack of studies examining the PANSS perilous behavior subscale in the global literature. A possible explanation is the fact that this subscale is only included in the Greek standardized version of the PANSS. Globally, a meta-analysis involving 45,533 patients with schizophrenia concluded that violent behavior in schizophrenia can be determined by elevated positive and total PANSS values [90].
The anxiogenic effects of caffeine are well documented [40,41]; however, no correlation was found between both the anxiety component of the general psychopathology PANSS subscale and the GAD-7 with caffeine serum levels. A cohort study that explored genetic susceptibility mediated via single nucleotide polymorphisms in the adenosine A2A receptor gene (ADORA2A) of 416 healthy individuals towards caffeine’s anxiogenic effects concluded that increasing caffeine consumption diminishes its anxiety-inducing effects irrespective of their genotype [38].
A plethora of studies in the literature report an amelioration of negative symptoms with increasing caffeine consumption. A recent cohort study in France that recruited 804 patients with schizophrenia spectrum disorder reported fewer negative symptoms as per the PANSS with caffeine consumption [73]. It is worth mentioning that coffee consumption was quantified based on patient-reported answers, and this association survived even after controlling for potential confounders such as demographic variables and tobacco consumption. A double-blind placebo study including 13 patients with schizophrenia also showed improvements in negative symptoms after acute caffeine administration. Improvements in withdrawal/retardation, mood, energy, and social involvement were observed after acute administration of 10 mg/kg p.o. caffeine in contrast to placebo (quinine) [69]. Conflicting results, on the other hand, in a large cohort study examining 250 patients with schizophrenia reported no association between caffeine consumption and negative symptoms but with smoking [91]. Patients in the current study exhibited fewer negative symptoms with caffeine serum levels. This association was significant in the poor rapport and passive/apathetic withdrawal component of the PANSS negative subscale and did not change significance when patients were grouped according to their caffeine drinking habits (caffeine consumers/non-consumers) or to their caffeine serum levels. While the connection between negative symptoms of schizophrenia and the adenosine hypothesis are very strong, i.e., patients with schizophrenia should theoretically present with fewer negative symptoms upon amelioration of the hypofunctioning adenosinergic network, no studies to date were able to discover a drug that acts on adenosine receptors with the aim of ameliorating negative symptoms [56].
These results, however, do not imply a causal effect of caffeine on symptom severity or cognition but merely indicate a correlation. Thereby, a different interpretation of these results should be taken into consideration, where caffeine would be consumed as a tool that patients with schizophrenia use to alleviate negative symptoms, or caffeine can be the psychostimulant in a subpopulation with an innate characteristic of aggression. In this context, a qualitative study in Australia reports that caffeine was used by patients with schizophrenia to increase alertness, while patients who reported negative experiences with caffeine decided to self limit its consumption [92]. Therefore, the clinical interpretation of our findings should be individually tailored to each patient and take into account their past history with caffeine consumption.

Limitations of the Study

Before the generalization of our results, several strengths limitations have to be considered. To the best of our knowledge, our study is one of the first ones investigating the impact of caffeine in schizophrenia patients in Europe and the only one in Greek patients diagnosed with schizophrenia. Furthermore, our results are based on serum level of caffeine measurements that objectively reflect caffeine consumption. On the other hand, the sample size was relatively small, which may limit the generalizability of the findings, making our results preliminary A future direction of our study will include an ROC analysis in order to determine a cut-off point of caffeine serum levels beyond which it is more probable to observe aggressive behavior. Additionally, a significant proportion of participants were smokers, and it is well established that smoking induces cytochrome P450 enzymes such as CYP1A2, which is responsible for the metabolism of caffeine [93]. However, the limited number of non-smokers hinders the ability to perform a multivariate analysis investigating the confounding role of smoking status. Another drawback of our study is based on the fact that our sample included patients with involuntary admission to hospitals and medication non-adherence, which constitute possible factors that drive patients to aggression [94]. Moreover, this was a cross-sectional study with a single assessment per patient, and no follow-up was conducted to monitor potential changes between the clinical picture and caffeine serum levels over time. Future research should consider larger samples with multiple assessment time points to monitor trends in symptomatology and caffeine consumption.

5. Conclusions

In summary, the preliminary results of our study highlight the significant associations between caffeine serum levels, symptom severity, and cognition among patients with schizophrenia. While the findings provide valuable insights, they should be interpreted with caution due to the study’s several limitations, the largest being the known effect of smoking on the metabolism of caffeine. More larger scale cohort studies are needed in order to elucidate the impact of caffeine consumption in patients with schizophrenia.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/brainsci16020209/s1, Figure S1: Distribution curve conveying the frequency distribution of caffeine serum levels in the study sample.

Author Contributions

Conceptualization, M.B.J., M.N.P. and E.A.; methodology, M.B.J., M.N.P. and E.A.; formal analysis, M.B.J. and A.A.S.; investigation, M.B.J., N.C., M.S., S.P. and M.N.P.; resources, E.A.; data curation, M.B.J.; writing—original draft preparation, M.B.J. and M.N.P.; writing—review and editing, A.A.S., E.A., N.C. and M.S.; supervision, E.A., N.C. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

The research is conducted in the operating framework of the University of Thessaly Innovation, Technology Transfer Unit and Entrepreneurship Center “One Planet Thessaly”, under the “University of Thessaly Grants for Scientific Publication Support” action and is funded by the Special Account of Research Grants of the University of Thessaly.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Faculty of Medicine, University of Thessaly, 899/8 March 2021.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to patient privacy considerations.

Acknowledgments

Special thanks to Elias Begas for providing useful tips for the chromatography techniques.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cappelletti, S.; Daria, P.; Sani, G.; Aromatario, M. Caffeine: Cognitive and physical performance enhancer or psychoactive drug? Curr. Neuropharmacol. 2015, 13, 71–88. [Google Scholar] [CrossRef] [Scilit]
  2. Temple, J.L.; Bernard, C.; Lipshultz, S.E.; Czachor, J.D.; Westphal, J.A.; Mestre, M.A. The Safety of Ingested Caffeine: A Comprehensive Review. Front. Psychiatry 2017, 8, 80. [Google Scholar] [CrossRef] [Scilit]
  3. Dews, P.B. Caffeine. Ann. Rev. Nutr. 1982, 2, 323–341. [Google Scholar] [CrossRef] [Scilit]
  4. Verster, J.C.; Koenig, J. Caffeine intake and its sources: A review of national representative studies. Crit. Rev. Food Sci. Nutr. 2018, 58, 1250–1259. [Google Scholar] [CrossRef] [Scilit]
  5. Fulgoni, V.L.; Keast, D.R.; Lieberman, H.R. Trends in intake and sources of caffeine in the diets of US adults: 2001–2010. Am. J. Clin. Nutr. 2015, 101, 1081–1087. [Google Scholar] [CrossRef] [Scilit]
  6. Statista. Global Coffee Consumption from 2012/13 to 2023/24 (in Million 60-Kilogram Bags). 2025. Available online: https://www.statista.com/statistics/292595/global-coffee-consumption/ (accessed on 15 September 2025).
  7. Bonati, M.; Latini, R.; Galletti, F.; Young, J.F.; Tognoni, G.; Garattini, S. Caffeine disposition after oral doses. Clin. Pharmacol. Ther. 1982, 32, 98–106. [Google Scholar] [CrossRef] [Scilit]
  8. Yesair, D.W.; Branfman, A.R.; Callahan, M.M. Human disposition and some biochemical aspects of methylxanthines. Prog. Clin. Biol. Res. 1984, 158, 215–233. [Google Scholar]
  9. Arnaud, M.J. Identification, kinetic and quantitative study of [2-14C] and [1-Me-14C]caffeine metabolites in rat’s urine by chromatographic separations. Biochem. Med. 1976, 16, 67–76. [Google Scholar] [CrossRef] [Scilit]
  10. Mumford, G.K.; Benowitz, N.L.; Evans, S.M.; Kaminski, B.J.; Preston, K.L.; Sannerud, C.A.; Silverman, K.; Griffiths, R.R. Absorption rate of methylxanthines following capsules, cola and chocolate. Eur. J. Clin. Pharmacol. 1996, 51, 319–325. [Google Scholar] [CrossRef] [Scilit]
  11. Fredholm, B.B.; Bättig, K.; Holmén, J.; Nehlig, A.; Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51, 83–133. [Google Scholar] [CrossRef] [Scilit]
  12. Fredholm, B.B. Methylxanthines; Springer: Berlin/Heidelberg, Germany, 2011; Volume 200. [Google Scholar]
  13. Vickroy, T.W.; Chang, S.-K.; Chou, C.-C. Caffeine-induced hyperactivity in the horse: Comparisons of drug and metabolite concentrations in blood and cerebrospinal fluid. J. Vet. Pharmacol. Ther. 2008, 31, 156–166. [Google Scholar] [CrossRef] [Scilit]
  14. European Food Safety Authority (EFSA). Scientific Opinion on the safety of caffeine. EFSA J. 2015, 13, 4102. [Google Scholar] [CrossRef] [Scilit]
  15. Nehlig, A. Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. Pharmacol. Rev. 2018, 70, 384–411. [Google Scholar] [CrossRef] [Scilit]
  16. Miners, J.O.; Birkett, D.J. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen. Pharmacol. Vasc. Syst. 1996, 27, 245–249. [Google Scholar] [CrossRef] [Scilit]
  17. Berthou, F.; Flinois, J.P.; Ratanasavanh, D.; Beaune, P.; Riche, C.; Guillouzo, A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab. Dispos. 1991, 19, 561–567. [Google Scholar] [CrossRef] [Scilit]
  18. Rasmussen, B.B.; Brix, T.H.; Kyvik, K.O.; Brøsen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002, 12, 473–478. [Google Scholar] [CrossRef] [Scilit]
  19. Tang-Liu, D.D.; Williams, R.L.; Riegelman, S. Disposition of caffeine and its metabolites in man. J. Pharmacol. Exp. Ther. 1983, 224, 180–185. [Google Scholar] [CrossRef] [Scilit]
  20. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2023 (GBD 2023) Results; IHME: Seattle, WA, USA, 2023; Available online: https://vizhub.healthdata.org/gbd-results/?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7 (accessed on 15 September 2025).
  21. Jongsma, H.E.; Turner, C.; Kirkbride, J.B.; Jones, P.B. International incidence of psychotic disorders, 2002–2017: A systematic review and meta-analysis. Lancet Public Health 2019, 4, e229–e244. [Google Scholar] [CrossRef] [Scilit]
  22. Shafer, A.; Dazzi, F. Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure. J. Psychiatr. Res. 2019, 115, 113–120. [Google Scholar] [CrossRef] [Scilit]
  23. Grube, B.S.; Bilder, R.M.; Goldman, R.S. Meta-analysis of symptom factors in schizophrenia. Schizophr. Res. 1998, 31, 113–120. [Google Scholar] [CrossRef] [Scilit]
  24. Jauhar, S.; Johnstone, M.; McKenna, P.J. Schizophrenia. Lancet 2022, 399, 473–486. [Google Scholar] [CrossRef] [Scilit]
  25. Weickert, T.W.; Goldberg, T.E.; Gold, J.M.; Bigelow, L.B.; Egan, M.F.; Weinberger, D.R. Cognitive Impairments in Patients with Schizophrenia Displaying Preserved and Compromised Intellect. Arch. Gen. Psychiatry 2000, 57, 907. [Google Scholar] [CrossRef] [Scilit]
  26. Kremen, W.S.; Seidman, L.J.; Faraone, S.V.; Toomey, R.; Tsuang, M.T. The paradox of normal neuropsychological function in schizophrenia. J. Abnorm. Psychol. 2000, 109, 743–752. [Google Scholar] [CrossRef]
  27. Owens, D.G.C.; Johnstone, E.C. The Disabilities of Chronic Schizophrenia—Their Nature and the Factors Contributing to their Development. Br. J. Psychiatry 1980, 136, 384–395. [Google Scholar] [CrossRef] [Scilit]
  28. Reichenberg, A. The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin. Neurosci. 2010, 12, 383–392. [Google Scholar] [CrossRef] [Scilit]
  29. Palmer, B.W.; Dawes, S.E.; Heaton, R.K. What do we know about neuropsychological aspects of schizophrenia? Neuropsychol. Rev. 2009, 19, 365–384. [Google Scholar] [CrossRef] [Scilit]
  30. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 1980, 137, 1518–1522. [CrossRef] [Scilit]
  31. Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. Science 1976, 192, 481–483. [Google Scholar] [CrossRef] [Scilit]
  32. Javitt, D.C.; Zukin, S.R.; Heresco-Levy, U.; Umbricht, D. Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. Schizophr. Bull. 2012, 38, 958–966. [Google Scholar] [CrossRef] [Scilit]
  33. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 48, 1301–1308. [Google Scholar] [CrossRef] [Scilit]
  34. Lara, D.R.; Souza, D.O. Schizophrenia: A purinergic hypothesis. Med. Hypotheses 2000, 54, 157–166. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Holtzman, S.G.; Mante, S.; Minneman, K.P. Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther. 1991, 256, 62–68. [Google Scholar] [CrossRef] [Scilit]
  36. Fredholm, B.B. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci. 1979, 1, 129–132. [Google Scholar] [CrossRef] [Scilit]
  37. Fredholm, B.B. Adenosine, Adenosine Receptors and the Actions of Caffeine. Pharmacol. Toxicol. 1995, 76, 93–101. [Google Scholar] [CrossRef] [Scilit]
  38. Rogers, P.J.; Hohoff, C.; Heatherley, S.V.; Mullings, E.L.; Maxfield, P.J.; Evershed, R.P.; Deckert, J.; Nutt, D.J. Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption. Neuropsychopharmacology 2010, 35, 1973–1983. [Google Scholar] [CrossRef] [Scilit]
  39. Leathwood, P.D.; Pollet, P. Diet-induced mood changes in normal populations. J. Psychiatr. Res. 1982, 17, 147–154. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Kaplan, G.B.; Greenblatt, D.J.; Ehrenberg, B.L.; Goddard, J.E.; Cotreau, M.M.; Harmatz, J.S.; Shader, R.I. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J. Clin. Pharmacol. 1997, 37, 693–703. [Google Scholar] [CrossRef] [Scilit]
  41. Sawyer, D.A.; Julia, H.L.; Turin, A.C. Caffeine and human behavior: Arousal, anxiety, and performance effects. J. Behav. Med. 1982, 5, 415–439. [Google Scholar] [CrossRef] [Scilit]
  42. Jarvis, M.J. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacology 1993, 110, 45–52. [Google Scholar] [CrossRef] [Scilit]
  43. Hameleers, P.A.H.M.; Van Boxtel, M.P.J.; Hogervorst, E.; Riedel, W.J.; Houx, P.J.; Buntinx, F.; Jolles, J. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum. Psychopharmacol. Clin. Exp. 2000, 15, 573–581. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Araújo, L.F.; Mirza, S.S.; Bos, D.; Niessen, W.J.; Barreto, S.M.; van der Lugt, A.; Vernooij, M.W.; Hofman, A.; Tiemeier, H.; Ikram, M.A. Association of Coffee Consumption with MRI Markers and Cognitive Function: A Population-Based Study. J. Alzheimer’s Dis. 2016, 53, 451–461. [Google Scholar] [CrossRef] [Scilit]
  45. Childs, E.; de Wit, H. Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology 2006, 185, 514. [Google Scholar] [CrossRef] [Scilit]
  46. Kelemen, W.L.; Creeley, C.E. Caffeine (4 mg/kg) influences sustained attention and delayed free recall but not memory predictions. Hum. Psychopharmacol. Clin. Exp. 2001, 16, 309–319. [Google Scholar] [CrossRef] [Scilit]
  47. Borea, P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol. Rev. 2018, 98, 1591–1625. [Google Scholar] [CrossRef] [Scilit]
  48. Ferré, S. Adenosine-dopamine interactions in the ventral striatum. Psychopharmacology 1997, 133, 107–120. [Google Scholar] [CrossRef] [Scilit]
  49. Ginés, S.; Hillion, J.; Torvinen, M.; Le Crom, S.; Casadó, V.; Canela, E.I.; Rondin, S.; Lew, J.Y.; Watson, S.; Zoli, M.; et al. Dopamine D1 and adenosine A 1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. USA 2000, 97, 8606–8611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Rivera-Oliver, M.; Moreno, E.; Álvarez-Bagnarol, Y.; Ayala-Santiago, C.; Cruz-Reyes, N.; Molina-Castro, G.C.; Clemens, S.; Canela, E.I.; Ferré, S.; Casadó, V.; et al. Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron. Mol. Neurobiol. 2019, 56, 797–811. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA 1991, 88, 7238–7241. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Ciruela, F.; Casadó, V.; Rodrigues, R.J.; Luján, R.; Burgueño, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; et al. Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1 –A2A Receptor Heteromers. J. Neurosci. 2006, 26, 2080–2087. [Google Scholar] [CrossRef] [Scilit]
  53. Cristóvão-Ferreira, S.; Navarro, G.; Brugarolas, M.; Pérez-Capote, K.; Vaz, S.H.; Fattorini, G.; Conti, F.; Lluis, C.; Riberio, J.A.; McCormick, P.J.; et al. A1R–A2AR heteromers coupled to Gs and Gi/0 proteins modulate GABA transport into astrocytes. Purinergic Signal. 2013, 9, 433–449. [Google Scholar] [CrossRef] [Scilit]
  54. Ferré, S. An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 2008, 105, 1067–1079. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. George, S.R.; O’Dowd, B.F.; Lee, S.P. G-Protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 2002, 1, 808–820. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Singer, P.; Yee, B.K. The adenosine hypothesis of schizophrenia into its third decade: From neurochemical imbalance to early life etiological risks. Front. Cell. Neurosci. 2023, 17, 1120532. [Google Scholar] [CrossRef] [Scilit]
  57. Mayo, K.M.; Falkowski, W.; Jones, C.A.H. Caffeine: Use and Effects in Long-Stay Psychiatric Patients. Br. J. Psychiatry 1993, 162, 543–545. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Strassnig, M.; Brar, J.S.; Ganguli, R. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr. Res. 2006, 86, 269–275. [Google Scholar] [CrossRef] [Scilit]
  59. Goiney, C.C.; Gillaspie, D.B.; Alvarez Villalba, C.L. Addressing Caffeine-induced Psychosis. Addict. Disord. Their Treat. 2012, 11, 146–149. [Google Scholar] [CrossRef] [Scilit]
  60. Hedges, D.W.; Woon, F.L.; Hoopes, S.P. Caffeine-Induced Psychosis. CNS Spectr. 2009, 14, 127–131. [Google Scholar] [CrossRef] [Scilit]
  61. Kim, A.; O’Hanlon, M. Caffeine and clinical change in a patient with schizophrenia on a long-stay ward. Ir. J. Psychol. Med. 2011, 28, 42–44. [Google Scholar] [CrossRef] [Scilit]
  62. Wang, H.R.; Woo, Y.S.; Bahk, W.M. Caffeine-induced psychiatric manifestations. Int. Clin. Psychopharmacol. 2015, 30, 179–182. [Google Scholar] [CrossRef] [Scilit]
  63. Topyurek, M.; Tibbo, P.; Núñez, C.; Stephan-Otto, C.; Good, K. Caffeine effects and schizophrenia: Is there a need for more research? Schizophr. Res. 2019, 211, 34–35. [Google Scholar] [CrossRef] [Scilit]
  64. Núñez, C.; Stephan-Otto, C.; Cuevas-Esteban, J.; Maria Haro, J.; Huerta-Ramos, E.; Ochoa, S.; Usall, J.; Brébion, G. Effects of caffeine intake and smoking on neurocognition in schizophrenia. Psychiatry Res. 2015, 230, 924–931. [Google Scholar] [CrossRef] [Scilit]
  65. Jabbar, S.B.; Hanly, M.G. Fatal Caffeine Overdose. Am. J. Forensic Med. Pathol. 2013, 34, 321–324. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Rudolph, T.; Knudsen, K. A case of fatal caffeine poisoning. Acta Anaesthesiol. Scand. 2010, 54, 521–523. [Google Scholar] [CrossRef] [Scilit]
  67. Bioh, G.; Gallagher, M.M.; Prasad, U. Survival of a highly toxic dose of caffeine. BMJ Case Rep. 2013, 2013, bcr2012007454. [Google Scholar] [CrossRef] [Scilit]
  68. Kerrigan, S.; Lindsey, T. Fatal caffeine overdose: Two case reports. Forensic Sci. Int. 2005, 153, 67–69. [Google Scholar] [CrossRef] [Scilit]
  69. Lucas, P.B.; Pickar, D.; Kelsoe, J.; Rapaport, M.; Pato, C.; Hommer, D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol. Psychiatry 1990, 28, 35–40. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Gandhi, K.K.; Williams, J.M.; Menza, M.; Galazyn, M.; Benowitz, N.L. Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug Alcohol. Depend. 2010, 110, 151–155. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Rosen, R.L.; Ramasubramani, R.S.; Benowitz, N.L.; Gandhi, K.K.; Williams, J.M. Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder. Psychiatry Res. 2023, 319, 114989. [Google Scholar] [CrossRef] [Scilit]
  72. Han Almis, B.; Tekin, A.; Hakyemez Geylani, G.; Baltaci, E.; Egeli, A. Is there a relationship between caffeine intake and smoking and positive and negative symptom severity in schizophrenia? Psychiatr. Danub. 2023, 35, 56–61. [Google Scholar] [CrossRef] [Scilit]
  73. Szoke, A.; Richard, J.R.; Fond, G.; Misdrahi, D.; Lajnef, M.; Aouizerate, B.; Boyer, L.; Berna, F.; Capdevielle, D.; André, M.; et al. Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia—Data from the FACE-SZ cohort. J. Psychiatr. Res. 2023, 161, 206–212. [Google Scholar] [CrossRef] [Scilit]
  74. Lykouras, E.; Botsis, A.; Oulis, P. The Positive and Negative Syndrome Scale (PANSS); Tsiveriotis Ed: Athens, Greece, 1994. (In Greek) [Google Scholar]
  75. Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13, 261–276. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Spitzer, R.L.; Kroenke, K.; Williams, J.B.W.; Löwe, B. A Brief Measure for Assessing Generalized Anxiety Disorder. Arch. Intern. Med. 2006, 166, 1092. [Google Scholar] [CrossRef] [Scilit]
  77. Hodges, J.R.; Larner, A.J. Addenbrooke’s Cognitive Examinations: ACE, ACE-R, ACE-III, ACEapp, and M-ACE. In Cognitive Screening Instruments: A Practical Approach [Internet]; Larner, A.J., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 109–137. [Google Scholar] [CrossRef] [Scilit]
  78. Mathuranath, P.S.; Nestor, P.J.; Berrios, G.E.; Rakowicz, W.; Hodges, J.R. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 2000, 55, 1613–1620. [Google Scholar] [CrossRef] [PubMed]
  79. Kourtesis, P.; Margioti, E.; Demenega, C.; Christidi, F.; Abrahams, S. A Comparison of the Greek ACE-III, M-ACE, ACE-R, MMSE, and ECAS in the Assessment and Identification of Alzheimer’s Disease. J. Int. Neuropsychol. Soc. 2020, 26, 825–834. [Google Scholar] [CrossRef] [Scilit]
  80. Begas, E.; Kouvaras, E.; Tsakalof, A.K.; Bounitsi, M.; Asprodini, E.K. Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva. Biomed. Chromatogr. 2015, 29, 1657–1663. [Google Scholar] [PubMed]
  81. Leucht, S.; Samara, M.; Heres, S.; Davis, J.M. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr. Bull. 2016, 42, S90–S94. [Google Scholar] [CrossRef] [Scilit]
  82. Woods, S.W. Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics. J. Clin. Psychiatry 2003, 64, 663–667. [Google Scholar] [CrossRef] [Scilit]
  83. Hany, M.; Rizvi, A. Schizophrenia; StatPearls Publishing: Treasure Island, FL, USA, 2025. [Google Scholar]
  84. Marder, S.R.; Cannon, T.D. Schizophrenia. N. Engl. J. Med. 2019, 381, 1753–1761. [Google Scholar] [CrossRef] [Scilit]
  85. Hellenic Statistical Authority, Greek National Survey. 2025. Available online: https://www.statistics.gr/greece-in-figures (accessed on 26 June 2025).
  86. Harvanko, A.M.; Derbyshire, K.L.; Schreiber, L.R.N.; Grant, J.E. The effect of self-regulated caffeine use on cognition in young adults. Hum. Psychopharmacol. Clin. Exp. 2015, 30, 123–130. [Google Scholar] [CrossRef] [Scilit]
  87. Strassnig, M.T.; Nascimento, V.; Deckler, E.; Harvey, P.D. Pharmacological treatment of violence in schizophrenia. CNS Spectr. 2020, 25, 207–215. [Google Scholar] [CrossRef] [Scilit]
  88. Zaslove, M.O.; Beal, M.; McKinney, R.E. Changes in Behaviors of Inpatients After a Ban on the Sale of Caffeinated Drinks. Hosp. Community Psychiatry 1991, 42, 84–85. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Carmel, H. Caffeine and Aggression. Hosp. Community Psychiatry 1991, 42, 637–638. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Witt, K.; van Dorn, R.; Fazel, S. Risk Factors for Violence in Psychosis: Systematic Review and Meta-Regression Analysis of 110 Studies. PLoS ONE 2013, 8, e55942. [Google Scholar] [CrossRef] [Scilit]
  91. Gurpegui, M.; Aguilar, M.C.; Martinez-Ortega, J.M.; Diaz, F.J.; de Leon, J. Caffeine Intake in Outpatients with Schizophrenia. Schizophr. Bull. 2004, 30, 935–945. [Google Scholar] [CrossRef] [Scilit]
  92. Thompson, L.; Pennay, A.; Zimmermann, A.; Cox, M.; Lubman, D.I. “Clozapine makes me quite drowsy, so when I wake up in the morning those first cups of coffee are really handy”: An exploratory qualitative study of excessive caffeine consumption among individuals with schizophrenia. BMC Psychiatry 2014, 14, 116. [Google Scholar] [CrossRef] [Scilit]
  93. Arrojo-Romero, M.; Armas Barbazán, C.; López-Moriñigo, J.D.; Ramos-Ríos, R.; Gurpegui, M.; Martínez-Ortega, J.M.; Jurado, D.; Diaz, F.J.; de Leon, J. Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. Schizophr. Res. 2015, 164, 234–241. [Google Scholar] [CrossRef] [Scilit]
  94. Walsh, E.; Buchanan, A.; Fahy, T. Violence and schizophrenia: Examining the evidence. Br. J. Psychiatry 2002, 180, 490–495. [Google Scholar] [CrossRef] [Scilit]
Brainsci 16 00209 g001
Figure 1. Pyramid plots displaying the difference in distribution amongst caffeine non-consumers and consumers in (A) poor rapport, (B) passive/apathetic social withdrawal, (C) danger profile subscore, (D) mannerisms and posturing, (E) poor attention, and (F) active social withdrawal.
Figure 1. Pyramid plots displaying the difference in distribution amongst caffeine non-consumers and consumers in (A) poor rapport, (B) passive/apathetic social withdrawal, (C) danger profile subscore, (D) mannerisms and posturing, (E) poor attention, and (F) active social withdrawal.
Brainsci 16 00209 g001
Brainsci 16 00209 g002
Figure 2. Pyramid plots displaying the difference in distribution amongst caffeine non-consumers and consumers in the (A) attention and orientation and (B) language ACE-R subscores.
Figure 2. Pyramid plots displaying the difference in distribution amongst caffeine non-consumers and consumers in the (A) attention and orientation and (B) language ACE-R subscores.
Brainsci 16 00209 g002
Table 1. Demographic characteristics of participants; data are represented as mean ± SD.
Table 1. Demographic characteristics of participants; data are represented as mean ± SD.
VariablesPANSS Arm n = 53ACE-R Arm n = 50
SexFemale1313
Male4037
Smoking statusNon-smoker2826
Smoker2524
Age (years)45 ± 1145 ± 11
Duration of disease (years)21.58 ± 10.7821.88 ± 10.80
Body Mass Index (kg/m2)28.98 ± 6.3429.16 ± 6.37
CPZ equivalent (mg)691.83 ± 425.37704.82 ± 426.08
Caffeine levels at baseline (μg/mL)0.543 ± 2.4510.617 ± 2.503
Table 2. Descriptive patient data in the PANSS arm; data are represented as mean ± SD.
Table 2. Descriptive patient data in the PANSS arm; data are represented as mean ± SD.
VariableMeasurement
Positive PANSS subscore15 ± 8
Negative PANSS subscore21 ± 7
Perilous behavior PANSS subscore7 ± 4
General Psychopathology PANSS subscore30 ± 9
Total PANSS score72 ± 21
Caffeine levels at baseline (μg/mL)1.589 ± 2.451
Table 3. Statistical analysis regarding PANSS variables and caffeine consumption. Mann–Whitney U test results comparing the distribution of symptoms across mean ranks of caffeine non-consumers (n = 25) and consumers (n = 28). * p < 0.05.
Table 3. Statistical analysis regarding PANSS variables and caffeine consumption. Mann–Whitney U test results comparing the distribution of symptoms across mean ranks of caffeine non-consumers (n = 25) and consumers (n = 28). * p < 0.05.
VariableCaffeine Non-Consumers
(n = 25)		Caffeine Consumers
(n = 28)		p
Positive PANSS subscore25.128.70.394
Delusions27.1426.880.948
Conceptual disorganization25.5628.290.489
Hallucinatory behavior24.629.140.225
Excitement23.2230.380.055
Grandiosity26.0227.880.483
Suspiciousness/persecution27.926.20.665
Hostility24.4229.30.128
Negative PANSS subscore29.7424.550.221
Blunted affect29.5224.750.248
Emotional withdrawal27.926.20.68
Poor rapport32.0222.520.017 *
Passive/apathetic social withdrawal31.6822.820.028 *
Difficulty in abstract thinking24.329.410.22
Lack of spontaneity and flow of conversation28.4825.680.492
Stereotyped thinking26.6827.290.875
Danger Profile PANSS subscore20.28330.002 *
Anger2231.460.013 *
Intolerance to deferred gratification22.2631.230.026 *
Emotional volatility20.1233.140.001 *
General Psychopathology PANSS subscore28.6625.520.459
Somatic concern27.726.380.66
Anxiety28.2825.860.543
Guilt feelings27.9826.130.538
Tension29.9224.390.139
Mannerisms and posturing31.2623.20.027 *
Depression29.624.680.169
Motor retardation29.8224.480.129
Uncooperativeness25.4628.380.349
Unusual thought content27.1826.840.928
Disorientation25.2428.570.284
Poor attention22.5630.960.033 *
Lack of judgement and insight25.1828.630.409
Disturbance of volition2826.110.495
Poor impulse control26.4227.520.738
Preoccupation24.4429.290.194
Active social avoidance32.4222.160.008 *
Total PANSS Score26.5627.390.845
Table 4. Spearman’s correlation coefficient of caffeine serum levels across PANSS subscores and its corresponding component items. * p < 0.05.
Table 4. Spearman’s correlation coefficient of caffeine serum levels across PANSS subscores and its corresponding component items. * p < 0.05.
Spearman’s Rhop Spearman’s Rhop
Positive PANSS subscore0.2090.133Emotional volatility *0.464<0.001
Delusions0.0530.706General Psychopathology PANSS subscore0.0170.902
Conceptual disorganization0.1940.164Somatic concern0.0340.808
Hallucinatory behavior0.1890.176Anxiety−0.0420.766
Excitement *0.3410.012Guilt feelings−0.10.477
Grandiosity0.1610.251Tension−0.140.318
Suspiciousness/persecution−0.0180.899Mannerisms and posturing−0.2270.103
Hostility *0.2760.045Depression−0.1450.301
Negative PANSS subscore−0.2020.147Motor retardation−0.2070.137
Blunted affect−0.1730.216Uncooperativeness0.1780.201
Emotional withdrawal−0.030.832Unusual thought content0.040.777
Poor rapport *−0.3490.01Disorientation0.1780.202
Passive/apathetic social withdrawal *−0.3870.004Poor attention *0.3370.013
Difficulty in abstract thinking0.1710.22Lack of judgement and insight0.1440.302
Lack of spontaneity and flow of conversation−0.1420.309Disturbance of volition−0.0450.748
Stereotyped thinking−0.020.887Poor impulse control0.1470.294
Perilous behavior PANSS subscore *0.4350.001Preoccupation0.2380.086
Anger *0.3350.014Active social avoidance *−0.3470.011
Intolerance to deferred gratification *0.3570.009Total PANSS Score0.1150.41
Table 5. ACE-R results.
Table 5. ACE-R results.
VariablesMeasurements
ACE-R attention and memory score16 ± 2
ACE-R memory score16 ± 6
ACE-R fluency score7 ± 3
ACE-R language score22 ± 3
ACE-R visuo-spatial score13 ± 2
Total ACE-R score75 ± 13
Table 6. Spearman’s correlation coefficient of caffeine serum levels across ACE-R subscores and its corresponding component items. * p < 0.05.
Table 6. Spearman’s correlation coefficient of caffeine serum levels across ACE-R subscores and its corresponding component items. * p < 0.05.
MW-U Test 23 vs. 27Spearman’s Correlation Test
pSpearman’s Rhop
Attention and orientation *0.042−0.3350.017 *
Memory0.977−0.0020.987
Fluency0.5240.1160.423
Language *0.005−0.4180.003
Visuo-spatial perception0.189−0.1770.218
Total ACE-R score0.501−0.1080.455
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Janho, M.B.; Papaliaga, M.N.; Samara, A.A.; Papoutsopoulou, S.; Speletas, M.; Christodoulou, N.; Asprodini, E. Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece. Brain Sci. 2026, 16, 209. https://doi.org/10.3390/brainsci16020209

AMA Style

Janho MB, Papaliaga MN, Samara AA, Papoutsopoulou S, Speletas M, Christodoulou N, Asprodini E. Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece. Brain Sciences. 2026; 16(2):209. https://doi.org/10.3390/brainsci16020209

Chicago/Turabian Style

Janho, Michel B., Maria N. Papaliaga, Athina A. Samara, Stamatia Papoutsopoulou, Matthaios Speletas, Nikolaos Christodoulou, and Eftihia Asprodini. 2026. "Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece" Brain Sciences 16, no. 2: 209. https://doi.org/10.3390/brainsci16020209

APA Style

Janho, M. B., Papaliaga, M. N., Samara, A. A., Papoutsopoulou, S., Speletas, M., Christodoulou, N., & Asprodini, E. (2026). Association Between Caffeine Levels and Symptom Profile in Schizophrenia: Results from a Cohort Study in Central Greece. Brain Sciences, 16(2), 209. https://doi.org/10.3390/brainsci16020209

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop